Chifei Kang

476 total citations
12 papers, 336 citations indexed

About

Chifei Kang is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Chifei Kang has authored 12 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 4 papers in Cancer Research and 3 papers in Oncology. Recurrent topics in Chifei Kang's work include Cancer, Lipids, and Metabolism (4 papers), Muscle Physiology and Disorders (3 papers) and Metabolism, Diabetes, and Cancer (3 papers). Chifei Kang is often cited by papers focused on Cancer, Lipids, and Metabolism (4 papers), Muscle Physiology and Disorders (3 papers) and Metabolism, Diabetes, and Cancer (3 papers). Chifei Kang collaborates with scholars based in United States, Finland and Switzerland. Chifei Kang's co-authors include Emily J. Gallagher, Derek LeRoith, Natalia Shirokova, Eeva‐Liisa Eskelinen, Viktoriia Kyrychenko, Ernst Niggli, Sergii Kyrychenko, Eva Polaková, Nina D. Ullrich and Tibor Rohács and has published in prestigious journals such as Journal of Neuroscience, Endocrinology and American Journal of Obstetrics and Gynecology.

In The Last Decade

Chifei Kang

12 papers receiving 332 citations

Peers

Chifei Kang

MB

ONCOL

CR

PHYSI

CCM

Chen Qu China

Javier A. Gomez United States

Nicole I. Hunger Australia

Matthias Muenzner Germany

Junfeng Sun China

Stamatis Theocharis Greece

О. Е. Мустафина Russia

Jae-Ryong Kim South Korea

Dianhong Zhang China

Chunchun Wei China

Chen Qu China

Chifei Kang

179 ×0.8

MB

40 ×0.4

ONCOL

75 ×1.1

CR

40 ×0.8

PHYSI

23 ×0.5

CCM

Citations per year, relative to Chifei Kang Chifei Kang (= 1×) peers Chen Qu

Countries citing papers authored by Chifei Kang

Since Specialization

Citations

This map shows the geographic impact of Chifei Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chifei Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chifei Kang more than expected).

Fields of papers citing papers by Chifei Kang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chifei Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chifei Kang. The network helps show where Chifei Kang may publish in the future.

Co-authorship network of co-authors of Chifei Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Chifei Kang. A scholar is included among the top collaborators of Chifei Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chifei Kang. Chifei Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Kang, Chifei, Luyu Liu, Cheng‐Yu Wu, et al.. (2023). The adenosinergic machinery in cancer: In-tandem insights from basic mechanisms to therapy. Frontiers in Immunology. 14. 1111369–1111369. 8 indexed citations

2.

Jordan, Stefan, et al.. (2023). OR16-05 25-Hydroxycholesterol Mediates The Effects Of Dyslipidemia On Triple Negative Breast Cancer Metastasis. Journal of the Endocrine Society. 7(Supplement_1). 1 indexed citations

3.

Kang, Chifei, Ran Rostoker, Deniz Demircioğlu, et al.. (2021). TMEM176B Regulates AKT/mTOR Signaling and Tumor Growth in Triple-Negative Breast Cancer. Cells. 10(12). 3430–3430. 11 indexed citations

4.

Kase, Nathan, et al.. (2020). The midlife transition and the risk of cardiovascular disease and cancer Part I: magnitude and mechanisms. American Journal of Obstetrics and Gynecology. 223(6). 820–833. 15 indexed citations

5.

Kang, Chifei, Gadi Shlomai, Irini Markella Antoniou, et al.. (2020). SUN-131 The Roles of Two Insulin Receptor Isoforms in Triple Negative Breast Cancer Growth. Journal of the Endocrine Society. 4(Supplement_1). 1 indexed citations

6.

Kang, Chifei, Irini Markella Antoniou, Evren U. Azeloglu, et al.. (2020). SAT-137 The Effect of Hypertriglyceridemia on Triple Negative Breast Cancer Progression. Journal of the Endocrine Society. 4(Supplement_1). 1 indexed citations

7.

Liu, Luyu, et al.. (2019). G _αq Sensitizes TRPM8 to Inhibition by PI(4,5)P ₂ Depletion upon Receptor Activation. Journal of Neuroscience. 39(31). 6067–6080. 21 indexed citations

8.

Gonzalez, J. Patrick, Jayalakshmi Ramachandran, Chifei Kang, et al.. (2018). Normalization of connexin 43 protein levels prevents cellular and functional signs of dystrophic cardiomyopathy in mice. Neuromuscular Disorders. 28(4). 361–372. 15 indexed citations

9.

Kang, Chifei, Derek LeRoith, & Emily J. Gallagher. (2018). Diabetes, Obesity, and Breast Cancer. Endocrinology. 159(11). 3801–3812. 154 indexed citations

10.

Kang, Chifei, et al.. (2017). Deficit in PINK1/PARKIN-mediated mitochondrial autophagy at late stages of dystrophic cardiomyopathy. Cardiovascular Research. 114(1). 90–102. 42 indexed citations

11.

Kyrychenko, Sergii, Eva Polaková, Chifei Kang, et al.. (2012). Hierarchical accumulation of RyR post-translational modifications drives disease progression in dystrophic cardiomyopathy. Cardiovascular Research. 97(4). 666–675. 40 indexed citations

12.

Park, Ji‐Hye, Eunjin Oh, Young‐Sun Choi, et al.. (2001). Synergistic effects of dexamethasone and genistein on the expression of Cdk inhibitor p21WAF1/CIP1 in human hepatocellular and colorectal carcinoma cells. International Journal of Oncology. 18(5). 997–1002. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact